Neurobiology of Aging
Volume 28, Issue 3 , Pages 357-370 , March 2007

Proteomic analysis of brain tissue from an Alzheimer's disease mouse model by two-dimensional difference gel electrophoresis

  • Daria Sizova

      Affiliations

    • Alzheimer's Disease Group, Paris Research Centre, Aventis Pharma, 94403 Vitry sur Seine Cedex, France
    • Corresponding Author InformationCorresponding author at: Department of Genetics, University of Pennsylvania School of Medicine, Clinical Research Building, Room 755, 415 Curie Boulevard, Philadelphia, PA 19104-6149, USA. Tel.: +1 215 898 2997; fax: +1 215 573 5157.
    • ,
  • Elodie Charbaut

      Affiliations

    • Alzheimer's Disease Group, Paris Research Centre, Aventis Pharma, 94403 Vitry sur Seine Cedex, France
    • Present address: Downstream Process Development, Laboratoires Serono SA, Zone Industrielle B, CH-1809 Fenil-sur-Corsier, Switzerland.
    • ,
  • François Delalande

      Affiliations

    • Laboratory of Bioorganic Mass-Spectrometry, ECPM, 67087 Strasbourg Cedex 2, France
    • ,
  • Florence Poirier

      Affiliations

    • Laboratory of Bioorganic Mass-Spectrometry, ECPM, 67087 Strasbourg Cedex 2, France
    • ,
  • Anthony A. High

      Affiliations

    • Laboratory of Bioorganic Mass-Spectrometry, ECPM, 67087 Strasbourg Cedex 2, France
    • ,
  • Fabienne Parker

      Affiliations

    • Functional Genomics Group, Paris Research Centre, Aventis Pharma, 94403 Vitry sur Seine Cedex, France
    • ,
  • Alain Van Dorsselaer

      Affiliations

    • Laboratory of Bioorganic Mass-Spectrometry, ECPM, 67087 Strasbourg Cedex 2, France
    • ,
  • Marc Duchesne

      Affiliations

    • Functional Genomics Group, Paris Research Centre, Aventis Pharma, 94403 Vitry sur Seine Cedex, France
    • ,
  • Anita Diu-Hercend

      Affiliations

    • Alzheimer's Disease Group, Paris Research Centre, Aventis Pharma, 94403 Vitry sur Seine Cedex, France

Received 17 February 2005 ,Revised 17 January 2006 ,Accepted 31 January 2006.

References 

  1. Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Localization and cell association of C1q in Alzheimer's disease brain. Exp Neurol. 1996;138:22–32
  2. Baker H, Grillo M, Margolis FL. Biochemical and immunocytochemical characterization of olfactory marker protein in the rodent central nervous system. J Comp Neurol. 1989;285:246–261
  3. Bales KR, Dodart JC, DeMattos RB, Holtzman DM, Paul SM. Apolipoprotein E, amyloid, and Alzheimer disease. Mol Interv. 2002;2:363–375
  4. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 1999;96:15233–15238
  5. Bigl M, Bruckner MK, Arendt T, Bigl V, Eschrich K. Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. J Neural Transm. 1999;106:499–511
  6. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, et al. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol. 2003;184:247–263
  7. Boyett KW, DiCarlo G, Jantzen PT, Jackson J, O’Leary C, Wilcock D, et al. Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res. 2003;28:83–93
  8. Buiakova OI, Baker H, Scott JW, Farbman A, Kream R, Grillo M, et al. Olfactory marker protein (OMP) gene deletion causes altered physiological activity of olfactory sensory neurons. Proc Natl Acad Sci USA. 1996;93:9858–9863
  9. Butterfield DA, Boyd-Kimball D, Castegna A. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J Neurochem. 2003;86:1313–1327
  10. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med. 2002;32:1050–1060
  11. Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med. 2000;51:543–569
  12. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet. 2004;363:1139–1146
  13. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 2002;33:562–571
  14. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II. Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem. 2002;82:1524–1532
  15. Chang TY, Chang CC, Lin S, Yu C, Li BL, Miyazaki A. Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and -2. Curr Opin Lipidol. 2001;12:289–296
  16. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J. Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol. 2003;28:51–64
  17. Chen JW, Dodia C, Feinstein SI, Jain MK, Fisher AB. 1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities. J Biol Chem. 2000;275:28421–28427
  18. Condorelli DF, Nicoletti VG, Barresi V, Conticello SG, Caruso A, Tendi EA, et al. Structural features of rat GFAP gene and identification of a novel alternative transcript. J Neurosci Res. 1999;56:219–228
  19. Cottrell BA, Galvan V, Banwait S, Gorostiza O, Lombardo CR, Williams T, et al. A pilot proteomic study of amyloid precursor interactors in Alzheimer's disease. Ann Neurol. 2005;58:277–289
  20. Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein+presenilin-1 transgenic mice. J Neurosci. 2003;23:5219–5226
  21. Farrar G, Altmann P, Welch S, Wychrij O, Ghose B, Lejeune J, et al. Defective gallium-transferrin binding in Alzheimer disease and down syndrome: possible mechanism for accumulation of aluminium in brain. Lancet. 1990;335:747–750
  22. Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci. 2004;24:6457–6465
  23. Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell. 2001;1:515–525
  24. Ginsberg SD, Hemby SE, Lee VM, Eberwine JH, Trojanowski JQ. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol. 2000;48:77–87
  25. Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem. 1966;13:655–669
  26. Gu Y, Hamajima N, Ihara Y. Neurofibrillary tangle-associated collapsin response mediator protein-2 (CRMP-2) is highly phosphorylated on Thr-509, Ser-518, and Ser-522. Biochemistry. 2000;39:4267–4275
  27. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965–973
  28. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997;17:7053–7059
  29. Kanninen K, Goldsteins G, Auriola S, Alafuzoff I, Koistinaho J. Glycosylation changes in Alzheimer's disease as revealed by a proteomic approach. Neurosci Lett. 2004;367:235–240
  30. Koch A, Thiemann M, Grabenbauer M, Yoon Y, McNiven MA, Schrader M. Dynamin-like protein 1 is involved in peroxisomal fission. J Biol Chem. 2003;278:8597–8605
  31. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol. 2005;167:527–543
  32. Liao LCD, Wang J, Duong DM, Losik TG, Gearing M, Rees HD, et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem. 2004;279:37061–37068
  33. Lubec G, Krapfenbauer K, Fountoulakis M. Proteomics in brain research: potentials and limitations. Prog Neurobiol. 2003;69:193
  34. Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl. 1999;57:161–177
  35. Manevich Y, Sweitzer T, Pak JH, Feinstein SI, Muzykantov V, Fisher AB. 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. Proc Natl Acad Sci USA. 2002;99:11599–11604
  36. Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol. 2001;158:1345–1354
  37. McDonald WH, Yates JR. Shotgun proteomics and biomarker discovery. Dis Markers. 2002;18:99–105
  38. Messing A, Brenner M. GFAP: functional implications gleaned from studies of genetically engineered mice. Glia. 2003;43:87–90
  39. Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y. Association of transferrin C2 allele with late-onset Alzheimer's disease. Hum Genet. 1997;101:126–129
  40. Piot-Grosjean O, Le Cudennec C, Dhenain M, Delay-Goyet P, Delatour B. In: Proceedings of the ninth international conference on Alzheimer's disease and related disorders. 2004;
  41. Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood–brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:555–567
  42. Price DL, Sisodia SS. Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med. 1994;45:435–446
  43. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol. 2001;3:905–912
  44. Ross GW, O’Callaghan JP, Sharp DS, Petrovitch H, Miller DB, Abbott RD, et al. Quantification of regional glial fibrillary acidic protein levels in Alzheimer's disease. Acta Neurol Scand. 2003;107:318–323
  45. Schonberger SJ, Edgar PF, Kydd R, Faull RL, Cooper GJ. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics. 2001;1:1519–1528
  46. Shen Y, Meri S. Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol. 2003;70:463–472
  47. Shin SJ, Lee SE, Boo JH, Kim M, Yoon YD, Kim SI, et al. Profiling proteins related to amyloid deposited brain of Tg2576 mice. Proteomics. 2004;4:3359–3368
  48. Tabernero A, Medina A, Sanchez-Abarca LI, Lavado E, Medina JM. The effect of albumin on astrocyte energy metabolism is not brought about through the control of cytosolic Ca2+ concentrations but by free-fatty acid sequestration. Glia. 1999;25:1–9
  49. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging. 2002;23:485–508
  50. Todorich BM, Connor JR. Redox metals in Alzheimer's disease. Ann NY Acad Sci. 2004;1012:171–178
  51. Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S. Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res. 2002;27:1245–1253
  52. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood–brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation. 2003;10:463–470
  53. van Beek J, Elward K, Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann NY Acad Sci. 2003;992:56–71
  54. Vercauteren FG, Clerens S, Roy L, Hamel N, Arckens L, Vandesande F, et al. Early dysregulation of hippocampal proteins in transgenic rats with Alzheimer's disease-linked mutations in amyloid precursor protein and presenilin 1. Mol Brain Res. 2004;132:241–259
  55. Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A, et al. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem. 2003;278:25179–25190
  56. Webster S, Glabe C, Rogers J. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun. 1995;217:869–875
  57. Wisniewski HM, Vorbrodt AW, Wegiel J. Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Ann NY Acad Sci. 1997;826:161–172
  58. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov. 2002;1:859–866
  59. Wolozin B, Brown J, Theisler C, Silberman S. The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev. 2004;10:127–146
  60. Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, et al. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis. 2003;12:97–109
  61. Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol. 1999;154:927–936

PII: S0197-4580(06)00044-3

doi: 10.1016/j.neurobiolaging.2006.01.011

Neurobiology of Aging
Volume 28, Issue 3 , Pages 357-370 , March 2007

Article Tools

* Image Usage & Resolution